A sturgeon-derived bioactive compound beneficially modulates nuclear receptors controlling metabolic functions in patients with metabolic syndrome

A sturgeon-derived bioactive compound beneficially modulates nuclear receptors controlling metabolic functions in patients with metabolic syndrome

Authors

  • Francesco Marotta ReGenera Research Group for Aging-Intervention, Milano, Italy
  • Aldo Lorenzetti ReGenera Research group for Aging Intervention, Milano
  • Roberto Catanzaro 2Dept of Internal Medicine, University of Catania, Catania, Italy
  • Nicola Zerbinati CMP-Medical Center, Pavia, Italy
  • Shalini Jain National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, USA.
  • Umberto Solimene WHO-cntr for Traditional Medicine & Biotechnology, University of Milano, Italy
  • Santos K. Yaduvanshi School of Studies in Biochemistry, Jiwaji University, Gwalior, India
  • Hariom Yadav National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, USA.
  • Chiara Sapienza
  • Nalini Srivastava
  • Michele Milazzo
  • Angelo Italia

Keywords:

marine collagen peptide, peroxisome proliferator-activated receptor (PPAR), liver X receptor, farnesoid X receptor, metabolic nuclear receptors, LD-1227, metabolic syndrome

Abstract

The aim of the present study was to test the possible effects of a novel sturgeon-derived compound  (LD-1227) on inflammatory markers related to metabolic nuclear receptors in patients with metabolic syndrome. The study population consisted of 76 patients with metabolic syndrome and 30 healthy subjects who were maintained to their current treatments and randomly supplemented: A) LD-1227 (n=38) or B) placebo (n=38) as compared to C) healthy controls (n=30). LD-1227 or placebo (water-soluble starch) were given daily at breakfast and dinner for three months. Levels of hs-CRP, IL-6, TNF-α, leptin and adiponectin/ resistin index were assayed at the entry, 1 month and 3 months afterwards. At the end of the study period, as compared to B group, LD-1227-treated patients showed a significant improvement of all parameters tested, irrespective of the presence of diabetes. In particular, levels of adiponectin and adiponectin/ resistin index significantly increased following LD-1227 administration. Although the metabolic syndrome remains a multifaceted condition requiring a complex approach, LD-1227 could be a potential safe therapeutic tool to be integrated into a wider treatment and preventive medicine schedule strategy.

Downloads

Published

19-06-2013

Issue

Section

ORIGINAL ARTICLES

How to Cite

1.
A sturgeon-derived bioactive compound beneficially modulates nuclear receptors controlling metabolic functions in patients with metabolic syndrome. Acta Biomed [Internet]. 2013 Jun. 19 [cited 2024 Jun. 13];84(1):53-60. Available from: https://www.mattioli1885journals.com/index.php/actabiomedica/article/view/2429

Most read articles by the same author(s)